Literature DB >> 21855289

The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock.

Dilek Memiş1, Mehmet Turan Inal, Necdet Sut.   

Abstract

BACKGROUND: Septic shock is the leading causes of death in intensive care units. In addition to generous fluid administration, inotropic agents are commonly used to improve cardiac output. The effects of inotropic agents on regional blood flow remains unknown.
OBJECTIVE: The aim of this study was to assess the effects of levosimendan vs dobutamine added to dopamine on liver functions assessed using noninvasive liver function monitoring (LiMON) in patients with septic shock.
DESIGN: Prospective analysis. MEASUREMENTS AND
RESULTS: We analyzed 30 patients with septic shock who were treated in an intensive care unit. Indocyanine green plasma disappearance rate (ICG-PDR) was conducted concurrently using the LiMON system. A dose of 0.3 mg/kg ICG was given through a cubital fossa vein as a bolus.
RESULTS: Statistical analysis showed that the variation of hemodynamic variables was different between groups. In our results, the increase in systolic blood pressure, diastolic blood pressure, and mean arterial pressure was significantly higher in levosimendan group than in dobutamine group (P < .05). There was a decrease in before- and after-infusion ICG-PDR values in dobutamine group (20.38 ± 4.83 vs 20.34 ± 5.30), and no statistical difference was detected (P = .649). There was an increase in before- and after-infusion ICG-PDR values in levosimendan group (18.70 ± 2.59 vs 21.65 ± 3.20), and a statistical difference was detected (P = .001). There was statistical difference between groups (P = .000).
CONCLUSION: These results suggest that levosimendan added to dopamine improves systemic hemodynamics and increases splanchnic perfusion assessed using the user-friendly noninvasive bedside system LiMON in patients with septic shock compared with dobutamine. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855289     DOI: 10.1016/j.jcrc.2011.06.008

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  20 in total

Review 1.  Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis.

Authors:  Geert Koster; Jørn Wetterslev; Christian Gluud; Jan G Zijlstra; Thomas W L Scheeren; Iwan C C van der Horst; Frederik Keus
Journal:  Intensive Care Med       Date:  2014-12-18       Impact factor: 17.440

2.  Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study.

Authors:  Glenn Hernandez; Alejandro Bruhn; Cecilia Luengo; Tomas Regueira; Eduardo Kattan; Andrea Fuentealba; Jorge Florez; Ricardo Castro; Andres Aquevedo; Ronald Pairumani; Paul McNab; Can Ince
Journal:  Intensive Care Med       Date:  2013-06-06       Impact factor: 17.440

3.  [Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].

Authors:  K Lenz; A Gegenhuber; F Firlinger; G Lohr; P Piringer
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-19       Impact factor: 0.840

4.  Combination era, using combined vasopressors showed benefits in treating septic shock patients: a network meta-analysis of randomized controlled trials.

Authors:  Chongxiang Chen; Lanlan Pang; Yanyan Wang; Tianmeng Wen; Wu Yu; Xiaolei Yue; Yuming Rong; Wei Liao
Journal:  Ann Transl Med       Date:  2019-10

5.  Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.

Authors:  Elena Grossini; Kevin Bellofatto; Serena Farruggio; Lorenzo Sigaudo; Patrizia Marotta; Giulia Raina; Veronica De Giuli; David Mary; Piero Pollesello; Rosalba Minisini; Mario Pirisi; Giovanni Vacca
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

6.  Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model.

Authors:  Cheng-Ming Tsao; Kai-Yi Li; Shiu-Jen Chen; Shuk-Man Ka; Wen-Jinn Liaw; Hsieh-Chou Huang; Chin-Chen Wu
Journal:  Crit Care       Date:  2014-11-29       Impact factor: 9.097

Review 7.  Hepatic Shock Differential Diagnosis and Risk Factors: A Review Article.

Authors:  Hassan Soleimanpour; Saeid Safari; Farzad Rahmani; Arezu Nejabatian; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2015-10-10       Impact factor: 0.660

Review 8.  Early prevention of trauma-related infection/sepsis.

Authors:  Xiao-Yuan Ma; Li-Xing Tian; Hua-Ping Liang
Journal:  Mil Med Res       Date:  2016-11-08

Review 9.  Levosimendan: current data, clinical use and future development.

Authors:  M S Nieminen; S Fruhwald; L M A Heunks; P K Suominen; A C Gordon; M Kivikko; P Pollesello
Journal:  Heart Lung Vessel       Date:  2013

10.  An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.

Authors:  Robert M L'E Orme; Gavin D Perkins; Daniel F McAuley; Kathleen D Liu; Alexina J Mason; Andrea Morelli; Mervyn Singer; Deborah Ashby; Anthony C Gordon
Journal:  Trials       Date:  2014-06-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.